Compare Neurocrine Biosciences Inc (NBIX) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.68. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| NBIX | YMAG | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $180.55 | $15.98 |
52-Week Low | $123.10 | $11.00 |
Enterprise Value | $16.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAG trades at $11.63, up 0.17% with a neutral technical signal. The ETF provides weekly dividend distributions, recently ranging from $0.07 to $0.40 per share. Key financial ratios are unavailable, but the fund's strategy focuses on option income from Magnificent Seven stocks. Recent news highlights consistent distribution announcements and tactical performance discussions.
Outlook hinges on option income strategy effectiveness in volatile markets. Opportunities include high yield potential, but risks involve NAV decay and expense ratio drag. Investor sentiment is mixed, with some analysts citing underperformance versus benchmarks amid low implied volatility reducing yield potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
